These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12739985)

  • 41. Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion.
    Eriksson UG; Dorani H; Karlsson J; Fritsch H; Hoffmann KJ; Olsson L; Sarich TC; Wall U; Schützer KM
    Drug Metab Dispos; 2006 May; 34(5):775-82. PubMed ID: 16455803
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical experience of melagatran/ximelagatran in major orthopaedic surgery.
    Eriksson BI
    Thromb Res; 2003 Jul; 109 Suppl 1():S23-9. PubMed ID: 12818631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
    Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Mouret P; Rosencher N; Eskilson C; Nylander I; Frison L; Ogren M;
    Thromb Haemost; 2003 Feb; 89(2):288-96. PubMed ID: 12574809
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
    Carlsson S; Elg M; Mattsson C
    Thromb Res; 2002 Aug; 107(3-4):163-8. PubMed ID: 12431484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. No influence of food on the pharmacokinetics, pharmacodynamics or tolerability of the 24mg and 36mg oral tablet formulations of ximelagatran.
    Ersdal E; Schützer KM; Lönnerstedt C; Ohlsson L; Wall U; Eriksson UG
    Clin Drug Investig; 2005; 25(7):425-33. PubMed ID: 17532684
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ximelagatran: an orally active direct thrombin inhibitor.
    Gulseth MP
    Am J Health Syst Pharm; 2005 Jul; 62(14):1451-67. PubMed ID: 15998925
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.
    Sarich TC; Eriksson UG; Mattsson C; Wolzt M; Frison L; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):300-5. PubMed ID: 11858491
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
    Wolzt M; Levi M; Sarich TC; Boström SL; Eriksson UG; Eriksson-Lepkowska M; Svensson M; Weitz JI; Elg M; Wåhlander K
    Thromb Haemost; 2004 Jun; 91(6):1090-6. PubMed ID: 15175794
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Ximelagatran/Melagatran. Perspectives for new oral antithrombin drugs].
    Samama MM
    J Mal Vasc; 2004 May; 29(2):61-2. PubMed ID: 15229400
    [No Abstract]   [Full Text] [Related]  

  • 51. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
    Eriksson BI; Bergqvist D; Kälebo P; Dahl OE; Lindbratt S; Bylock A; Frison L; Eriksson UG; Welin L; Gustafsson D;
    Lancet; 2002 Nov; 360(9344):1441-7. PubMed ID: 12433510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanism of action of the oral direct thrombin inhibitor ximelagatran.
    Mattsson C; Sarich TC; Carlsson SC
    Semin Vasc Med; 2005 Aug; 5(3):235-44. PubMed ID: 16123910
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
    Mehta JL; Chen L; Nichols WW; Mattsson C; Gustafsson D; Saldeen TG
    J Cardiovasc Pharmacol; 1998 Mar; 31(3):345-51. PubMed ID: 9514177
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics, preliminary efficacy and safety of subcutaneous melagatran and oral ximelagatran : a multicentre study of thromboprophylaxis in elective abdominal surgery.
    Bergqvist D; Solhaug JH; Holmdahl L; Eriksson UG; Andersson M; Boberg B; Ogren M
    Clin Drug Investig; 2004; 24(3):127-36. PubMed ID: 17516699
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes.
    Gustafsson D; Antonsson T; Bylund R; Eriksson U; Gyzander E; Nilsson I; Elg M; Mattsson C; Deinum J; Pehrsson S; Karlsson O; Nilsson A; Sörensen H
    Thromb Haemost; 1998 Jan; 79(1):110-8. PubMed ID: 9459334
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran, and the intermediate metabolites, in biological samples by liquid chromatography-mass spectrometry.
    Larsson M; Ahnoff M; Abrahamsson A; Logren U; Fakt C; Ohrman I; Persson BA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jan; 783(2):335-47. PubMed ID: 12482476
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatran.
    Boström SL; Dagnelid E; Hansson GF; Ulvinge JC
    Blood Coagul Fibrinolysis; 2004 Jan; 15(1):25-30. PubMed ID: 15166940
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
    Heit JA; Colwell CW; Francis CW; Ginsberg JS; Berkowitz SD; Whipple J; Peters G;
    Arch Intern Med; 2001 Oct; 161(18):2215-21. PubMed ID: 11575978
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biliary excretion of ximelagatran and its metabolites and the influence of erythromycin following intraintestinal administration to healthy volunteers.
    Matsson EM; Eriksson UG; Knutson L; Hoffmann KJ; Logren U; Fridblom P; Petri N; Lennernäs H
    J Clin Pharmacol; 2011 May; 51(5):770-83. PubMed ID: 20663994
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ximelagatran: pharmacokinetics and pharmacodynamics of a new strategy for oral direct thrombin inhibition.
    Kereiakes DJ
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S4-11. PubMed ID: 15619615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.